Tanabe Pharma Corporation
Clinical trials sponsored by Tanabe Pharma Corporation, explained in plain language.
-
New drug trial targets hardening skin in rare autoimmune disease
Disease control OngoingThis study is testing whether an investigational drug called MT-0551 can reduce skin thickening in people with systemic sclerosis, a rare autoimmune disease that causes hardening of the skin and internal organs. The trial will compare MT-0551 against a placebo in 80 patients over…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Apr 04, 2026 06:35 UTC
-
New hope for Tough-to-Treat blood cancer
Disease control OngoingThis study is testing a new drug called MT-2111 for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has returned or hasn't responded to at least two prior treatments. The first part checks the drug's safety and the best dose, while…
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC